Cutaneous lupus erythematosus
MONDO:0005282An autoimmune disorder that manifests as different lupus-specific skin disorders; it can occur with systemic lupus erythematosus, or as a singular disease.
Also known as: lupus erythematosus, cutaneous
81 clinical trials for this condition and its sub-types, 38 tagged with Cutaneous lupus erythematosus itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Cutaneous lupus erythematosus
-
Chronic cutaneous lupus erythematosus 3 trials · 23 incl. sub-types
5 sub-types
- Discoid lupus erythematosus 17 trials
- Chilblain lupus 1 trial · 3 incl. sub-types Sub-types →
- Lupus erythematosus tumidus 3 trials
- Hypertrophic or verrucous lupus erythematosus 0 trials
- Lupus erythematosus panniculitis 0 trials
-
Subacute cutaneous lupus erythematosus 11 trials
-
Rowell syndrome 0 trials
-
Bullous systemic lupus erythematosus 0 trials
Most studied deeper sub-types
-
Continued anifrolumab treatment studied for lupus and related diseases
Disease control Not yet recruitingThis study offers continued access to anifrolumab (Saphnelo) for people with systemic lupus erythematosus, systemic sclerosis, or myopathies who completed a prior anifrolumab trial and are still benefiting from the drug. Participants receive the same treatment as before, while re…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New lupus drug candidate enters early human safety testing
Disease control Not yet recruitingThis early-stage study tests a new medicine called HC022 in 32 adults with lupus (SLE or CLE). The main goal is to see if the drug is safe and how the body handles it. Participants will receive multiple doses or a placebo, and researchers will monitor for side effects and measure…
Phase 1 • Sponsor: HC Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill aims to tame painful lupus skin flares
Disease control Not yet recruitingThis study is testing whether a pill called enpatoran can safely reduce active skin rashes in people with lupus. About 202 participants with moderate-to-severe lupus skin symptoms will take either enpatoran or a placebo pill for 24 weeks, while continuing their standard lupus med…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New lupus drug candidate begins first safety tests in humans
Knowledge-focused Not yet recruitingThis early-stage study will test the safety and tolerability of a new drug called ACT100 in 48 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure how the drug moves through the body. This is the first …
Phase 1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC